Fifth Third Bancorp Raises Position in Moderna, Inc. $MRNA

Fifth Third Bancorp lifted its stake in shares of Moderna, Inc. (NASDAQ:MRNA) by 52.9% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 32,088 shares of the company’s stock after buying an additional 11,108 shares during the quarter. Fifth Third Bancorp’s holdings in Moderna were worth $829,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Parkside Financial Bank & Trust grew its position in Moderna by 19.0% in the second quarter. Parkside Financial Bank & Trust now owns 2,347 shares of the company’s stock valued at $65,000 after acquiring an additional 375 shares in the last quarter. Amalgamated Bank lifted its position in shares of Moderna by 0.6% during the second quarter. Amalgamated Bank now owns 65,458 shares of the company’s stock worth $1,806,000 after purchasing an additional 408 shares in the last quarter. Rothschild Investment LLC boosted its stake in shares of Moderna by 94.1% in the second quarter. Rothschild Investment LLC now owns 920 shares of the company’s stock valued at $25,000 after purchasing an additional 446 shares during the period. 180 Wealth Advisors LLC grew its holdings in Moderna by 2.8% during the 2nd quarter. 180 Wealth Advisors LLC now owns 23,928 shares of the company’s stock valued at $660,000 after purchasing an additional 642 shares in the last quarter. Finally, State of Michigan Retirement System grew its holdings in Moderna by 0.8% during the 2nd quarter. State of Michigan Retirement System now owns 92,541 shares of the company’s stock valued at $2,553,000 after purchasing an additional 700 shares in the last quarter. 75.33% of the stock is owned by institutional investors and hedge funds.

Key Headlines Impacting Moderna

Here are the key news stories impacting Moderna this week:

• Positive Sentiment: FDA will review Moderna’s mRNA flu vaccine application after an initial refusal-to-file, with regulators now targeting a decision by Aug. 5, 2026 — a reversal that boosts the commercial outlook for a new recurring vaccine market and spurred an earlier jump in the stock. Moderna Stock Jumps After FDA Reverses Course on Flu Shot
• Positive Sentiment: Goldman Sachs analyst flagged upside for MRNA, an institutional vote of confidence that can support sentiment and buying interest. Moderna (NASDAQ:MRNA) Stock Price Expected to Rise, The Goldman Sachs Group Analyst Says
• Neutral Sentiment: Moderna will present at TD Cowen and Barclays healthcare conferences in March — routine investor access that may provide more management detail but is unlikely by itself to move the stock dramatically. Moderna to Present at Upcoming Conferences in March 2026
• Negative Sentiment: BioNTech sued Moderna in Delaware federal court alleging Moderna’s mNexspike infringes a patent tied to BioNTech/Pfizer’s Comirnaty—new litigation increases legal risk, potential damages or injunctions, and heightens competitive/legal uncertainty for Moderna’s COVID-19/respiratory vaccine portfolio. BioNTech sues Moderna for patent infringement over COVID-19 shots
• Negative Sentiment: A court recently rejected two of Moderna’s defenses in its patent dispute with Arbutus, representing another legal setback that could increase exposure and costs from long-running mRNA technology litigation. Court Rejects Two Moderna Defenses in mRNA Vaccine Patent Row With Arbutus

Moderna Stock Up 0.3%

NASDAQ:MRNA opened at $49.87 on Friday. The company has a market capitalization of $19.49 billion, a price-to-earnings ratio of -6.86 and a beta of 1.32. Moderna, Inc. has a one year low of $22.28 and a one year high of $55.20. The stock has a 50-day simple moving average of $39.02 and a 200 day simple moving average of $30.44. The company has a debt-to-equity ratio of 0.07, a quick ratio of 3.22 and a current ratio of 3.29.

Moderna (NASDAQ:MRNA) last announced its quarterly earnings data on Friday, February 13th. The company reported ($2.11) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.79) by $0.68. Moderna had a negative return on equity of 30.15% and a negative net margin of 145.16%.The firm had revenue of $678.00 million for the quarter, compared to analysts’ expectations of $611.14 million. During the same quarter in the prior year, the firm posted ($2.91) earnings per share. Moderna’s revenue for the quarter was down 33.2% compared to the same quarter last year. Sell-side analysts predict that Moderna, Inc. will post -9.61 EPS for the current fiscal year.

Insider Activity

In related news, Director Noubar Afeyan sold 23,853 shares of the company’s stock in a transaction that occurred on Thursday, December 11th. The stock was sold at an average price of $29.48, for a total transaction of $703,186.44. Following the sale, the director directly owned 3,924 shares of the company’s stock, valued at approximately $115,679.52. This represents a 85.87% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 10.90% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on MRNA shares. Piper Sandler reiterated an “overweight” rating on shares of Moderna in a report on Monday, December 1st. TD Cowen reiterated a “hold” rating on shares of Moderna in a research note on Thursday, January 29th. BMO Capital Markets raised Moderna from a “market perform” rating to a “buy” rating in a report on Monday, January 12th. Morgan Stanley set a $30.00 price objective on Moderna in a report on Monday. Finally, Sanford C. Bernstein reaffirmed a “market perform” rating and issued a $45.00 target price on shares of Moderna in a research report on Tuesday. Two analysts have rated the stock with a Buy rating, thirteen have given a Hold rating and five have given a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Reduce” and a consensus target price of $31.47.

Moderna Profile

Moderna, Inc is a biotechnology company headquartered in Cambridge, Massachusetts, specializing in messenger RNA (mRNA) therapeutics and vaccines. The company’s platform leverages synthetic mRNA to instruct cells to produce proteins that can prevent or treat diseases. Since its founding in 2010, Moderna has advanced from early-stage research into a broad pipeline of vaccine and therapeutic candidates designed to address infectious diseases, rare genetic disorders and chronic illnesses.

Moderna’s flagship product is its mRNA-based COVID-19 vaccine, which was the first of its kind to receive emergency use authorization and later full approval in multiple jurisdictions.